Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

229 results about "Cardiac muscle cell" patented technology

Cardiac muscle cells or cardiomyocytes (also known as myocardiocytes or cardiac myocytes) are the muscle cells (myocytes) that make up the cardiac muscle (heart muscle). Each myocardial cell contains myofibrils, which are specialized organelles consisting of long chains of sarcomeres, the fundamental contractile units of muscle cells.

Generation of cardiomyocytes from human pluripotent stem cells

Methods for generating high-yield, high-purity cardiomyocyte progenitors or cardiomyocytes from pluripotent cells are described. Wnt / β-catenin signaling is first activated in pluripotent cells, e.g., by inhibition of Gsk-3 to obtain a first population of cells. Wnt / β-catenin signaling is then inhibited in the first cell population to induce cardiogenesis under fully defined, growth factor free culture conditions.
Owner:WISCONSIN ALUMNI RES FOUND

VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF

The present invention generally relates to methods and compositions to generate a secondary iPS (2iPS) cell to produce somatic cells of a rare differentiation cell type fate. In some embodiments, the method relates to an increase in efficiency of differentiation and production of high yields of somatic cells of a rare differentiation cell type fate produced from secondary iPS (2iPS) cells as compared to their differentiation from other pluripotent stem cell sources such as ES cells or primary iPS cells. In some embodiments, the present invention relates to compositions, methods and systems for reprogramming a first somatic cell into a primary iPS cell, where the primary iPS cell is then differentiated along a selected linage to produce a second somatic cell, which is then reprogrammed to a secondary iPS cell (2iPS) cell. The 2iPS cell has a high efficiency of differentiating into a cell of the same cell type as the second somatic cell, e.g., a somatic cells of a rare differentiation cell type fate such as but not limited to a ventricular cardiomyocyte, a pancreatic β-cell or a hepatic cell. In some embodiments, the first somatic cell is a fibroblast, or a cardiac cell, but is not limited to cardiac fibroblast cells. In some embodiments, the present invention relates to compositions, methods and systems to produce ventricular cardiomyocytes from secondary induced pluripotent stem cells (iPSC), where the iPSC are themselves generated from ventricular cardiomyocytes. The secondary iPS (2iPS) cell generated from ventricular cardiomyocytes have a higher cardiomyogenic potential and high cardiomyogenic yield as compared to primary iPSC, and are useful in drug discovery, disease modeling and cell-based therapy.
Owner:THE GENERAL HOSPITAL CORP

Use of human stem cells and/or factors they produce to promote adult mammalian cardiac repair through cardiomyocyte cell division

A method for treating a subject afflicted with a cardiac disorder, in vivo, comprising (i) producing a solution comprising media conditioned from the culture of cells, in vitro, and (ii) administering the solution of step (i) to the subject, thereby treating the cardiac disorder in the subject. Methods for determining whether an agent stimulates or inhibits myocyte proliferation.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Use of lifr or fgfr3 as a cell surface marker for isolating human cardiac ventricular progenitor cells

The present invention provides LIFR and FGFR3 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ LIFR+ ventricular progenitor cells and / or Islet 1+ / FGFR3+ ventricular progenitor cells and / or Islet 1+ / LIFR+ / FGFR3+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated LIFR+ and / or FGFR3+ ventricular progenitor cells are also provided. Methods of in vivo use of LIFR+ and / or FGFR3+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the LIFR+ and / or FGFR3+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided.
Owner:PROCELLA THERAPEUTICS AB

Cardiac muscle cell detection method based on inverse opal structure hydrogel and application thereof

The invention discloses a cardiac muscle cell detection method based on inverse opal structure hydrogel and application thereof. The detection method comprises the following steps: (1) preparing inverse opal structure hydrogel of biocompatibility; (2) culturing cardiac muscle cells based on inverse opal structure hydrogel; (3) detecting the cardiac muscle cells; (4) analyzing data. The inverse opal structure hydrogel in the invention has good biocompatibility, cells have high activity and phenotype when growing on the surface of the hydrogel, the inverse opal structure hydrogel not only provides a carrier for the growth of the cardiac muscle cells, but also provides a stable optical sensing signal for detecting the cardiac muscle cell shrinking force and hopping frequency. The detection method does not need a complicated detection system, and has the advantages of intuitiveness, high sensitivity, high efficiency and capability of preventing the influence of external conditions; the method can be used for screening and evaluating heart drugs and can screen the drugs by virtue of the variation of the cardiac muscle cell shrinking force and hopping frequency after the drug is added.
Owner:SOUTHEAST UNIV

Natural protein/polycaprolactone nanofiber electrospun membrane, and preparation and application thereof

The invention provides a natural protein / polycaprolactone nanofiber electrospun membrane, and preparation and application thereof. The natural protein / polycaprolactone nanofiber electrospun membrane is obtained by mixing natural protein and polycaprolactone to prepare a spinning solution and performing electrospinning, and the natural protein comprises natural elastin and natural collagen. The natural protein containing cardiac muscle tissue extracellular matrix components is mixed with an artificially synthesized degradable material, and the nanofiber membrane can be prepared quickly and effectively through an electrostatic spinning technically. The natural protein / polycaprolactone nanofiber electrospun membrane has the advantages that preparation is simple, materials are easy to obtain, and preparation cost is low. The natural protein / polycaprolactone nanofiber electrospun membrane not only has a good biomechanical property, but also can fully simulate cardiac muscle tissue extracellular matrix environment. Biological simulation can be carried out in the aspects of the structure and the ingredient, and an effect of treating myocardial infarction by stem cell transplantation is improved. Therefore, the natural protein / polycaprolactone nanofiber electrospun membrane can serve as an extracellular culture medium to provide an extracellular matrix microenvironment for promoting cell adhesion, survival and multiplication.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Self circulation organ chip dynamic culture device driven by cardiac muscle cell micro pump

PendingCN108300660ASolve the problem that the drive needs external energy supplyReduce volumeTissue/virus culture apparatusSpecific use bioreactors/fermentersVertical vibrationExternal energy
The invention provides a self circulation organ chip dynamic culture device driven by a cardiac muscle cell micro pump. The device comprises a lower layer chip, a middle film and an upper layer chip in sequential laminated arrangement from bottom to top, wherein the upper layer chip comprises a cardiac muscle cell micro pump module; the lower layer chip comprises a self circulation system module and an organ chip culture module; the self circulation system module is communicated with the organ chip culture module; the cardiac muscle cell micro pump module is used for simulating the blood pumping function of the heart; the self circulation system module is used for simulating the human body blood circulation loop; the organ chip culture module is used for simulating the human body organ function; the vertical vibration of the middle film is driven through the independent beating of the cardiac muscle cells growing in the cardiac muscle cell micro pump module; the self circulation flowing of culture liquid in the self circulation system module is realized; nutrient substances of the organ chip culture module are dynamically supplied. The self circulation organ chip dynamic culture device has the advantages that the external energy supply is not needed; the environment is more similar to the human body biomimetic environment; the size is reduced.
Owner:SHENZHEN GRADUATE SCHOOL TSINGHUA UNIV

Induction factor for inducing differentiation of iPS (induced pluripotent stem) cells into cardiac muscle cells and application thereof

The invention belongs to the field of regenerative medicine of cardiac muscle tissues, and discloses application of ascorbic acid as an induction factor in inducting differentiation of iPS (induced pluripotent stem) cells into cardiac muscle cells and a differentiation-inducing culture medium containing ascorbic acid. The invention also discloses a method for inducing differentiation of iPS cells into cardiac muscle cells by using the differentiation-inducing culture medium, which comprises the following step: inducing an iPS cell derived embryoid body, which has grown in a suspension mode for 5-7 days, to differentiate by utilizing the differentiation-inducing culture medium, thereby obtaining cardiac muscle cells. By using ascorbic acid as the induction factor, the invention obviously enhances the differentiation efficiency of the iPS cells into the cardiac muscle cells, and the differentiation percentage can reach 50-60%; the differentiation-inducing culture medium does not have toxic or side effect on the cells; and in addition, the method provided by the invention is simple, has the advantage of low cost, can be operated in common laboratories, and is suitable for large-scale proceeding.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products